Shareholder Update February 2022

Dear Conscious Mind Labs Shareholders,

A belated Happy New Year and Year of The Tiger! I can’t believe that we’re one month into 2022 already. It reminds me of a saying I recently read, “It is not enough to be busy. So are the ants. The question is: What are we busy about?”

Well, what have we been busy about? Over the past year, my team and I have worked hard to set the fundamentals in order to build and maximize shareholder value moving forward. The goal has always been to differentiate ourselves from others in our space with our revenue-focused and research driven mindset. 2021 has been a busy year to do just this:

> I have been busy in the lab formulating a variety of both medicinal and psychedelic mushroom formulations along with a portfolio of holistic and cognitive health supplements. In 2021, we submitted over 20 Product License Applications (PLA’s) to Health Canada and look forward in announcing updates on this shortly. Regulatory approval by Health Canada and NPNs are essential to our success in marketing and selling supplements and health products in the Canadian market. We have some exciting plans for our Consumer-Packaged Goods Division in 2022 as we set in motion the first products in the Conscious Mind Medicinal Mushroom Series in Canada sometime in Q3;

> We launched our flagship “Conscious Mind Clinic” in Vancouver, BC. Headed by our Chief Medical Officer, Dr. Jody Toor, the Conscious Mind Clinic will employ a wide range of modalities as part of its personalized treatment offerings, including psychedelic therapy and integration, breathwork, meditation, mindfulness therapy. Dr. Toor has been strategically building our team of practitioners at the Vancouver Clinic to give us the ability to facilitate psychedelic healing journeys with Indigenous plant medicines. Our flagship clinic should be fully operational by Q2, at which time, we plan on expanding our footprint across Canada and into the USA and will have more on these plans as we execute on this significant opportunity;

> Dr. Gregory Bigford, our Chief Scientific Officer, has been hard at work with our research & development efforts, writing the protocol for a neuroimaging clinical study on psilocybin and its effects on treating major depressive disorder (treatment resistant depression). We hope to be able to update more on Dr. Bigford’s active engagement this past year with a prestigious research institute as the proposed site for the study very soon. The study addresses the Conscious Mind vision to develop innovative treatment protocols tailored to different neurodegenerative diseases, including mental health conditions, such as depression, PTSD and addiction. The project addresses the growing mental health epidemic and the recognized need for novel treatments and medicines for treatment resistant conditions. This initiative will position us as a world-class leader in the research and development of innovative psychedelic drug treatments for mental health conditions;

> Our Chief Mycologist, Craig Wilkie, has been busy isolating and cataloging our proprietary strains of mushroom genetics as we continue to build this IP portfolio. His portfolio includes a wide variety of psilocybin-based mushroom genetics, in addition to some unique R&D advancements with functional mushrooms, such as Lion’s Mane. Furthermore, we’ve been working on a variety of proprietary extraction methods for the Amanita muscaria (Fly Agaric) mushroom, which is the most recognized mushroom in the world (i.e. Think Super Mario, the video game & it’s Super Mushroom). Amanita muscaria is an under-studied medicinal mushroom with psychedelic properties. Amanita mushrooms works much differently than psilocybin mushrooms and have mainly sedative and anti-anxiety properties. In conjunction with these R&D initiatives and in line with our revenue focussed, research driven mindset we have applications in with Health Canada to market and sell 4 different concentrations of Amanita muscaria tinctures;

> And finally, I am happy to announce that our “go public” initiative is moving forward. Near the end of 2021, we successfully executed on our go public initiatives with the signing of our proposed Reverse-Take-Over (RTO) with reporting issuer, RECO. This takes us one step closer in becoming a publicly traded company. The past year has been a tumultuous ride for publicly traded companies in our space but I am very excited to see that the market interest in our space is picking up with renewed interest. This bodes well with our timing as we hope to complete this process sometime in Q2 of this year. I’m hoping to provide further updates on timing and updates on this shortly.

2021 has certainly been a very productive year and we’re excited for 2022 as we execute in what we expect to be a breakout year. On behalf of my team and I we’d like to thank you for your support as we continue to build Conscious Mind Labs into a global player in the mental health and wellness space. There’ll always be challenges but I see tremendous opportunity in front of us and am confident that we have the team in place to capitalize. I look forward to continuing this journey together as we build our company!


Donald Gauvreau
Founder & CEO